367 related articles for article (PubMed ID: 27881555)
1. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
Gibson CM; Pinto DS; Chi G; Arbetter D; Yee M; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Burton P; van Eickels M; Korjian S; Daaboul Y; Jain P; Lip GY; Cohen M; Peterson ED; Fox KA
Circulation; 2017 Jan; 135(4):323-333. PubMed ID: 27881555
[TBL] [Abstract][Full Text] [Related]
2. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
Gibson CM; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Birmingham M; Ianus J; Burton P; van Eickels M; Korjian S; Daaboul Y; Lip GY; Cohen M; Husted S; Peterson ED; Fox KA
N Engl J Med; 2016 Dec; 375(25):2423-2434. PubMed ID: 27959713
[TBL] [Abstract][Full Text] [Related]
4. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
[TBL] [Abstract][Full Text] [Related]
6. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
7. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
Chi G; Yee MK; Kalayci A; Kerneis M; AlKhalfan F; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
J Thromb Thrombolysis; 2018 Oct; 46(3):346-350. PubMed ID: 29943350
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
De Vriese AS; Caluwé R; Van Der Meersch H; De Boeck K; De Bacquer D
J Am Soc Nephrol; 2021 Jun; 32(6):1474-1483. PubMed ID: 33753537
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.
Blin P; Fauchier L; Dureau-Pournin C; Sacher F; Dallongeville J; Bernard MA; Lassalle R; Droz-Perroteau C; Moore N
Stroke; 2019 Sep; 50(9):2469-2476. PubMed ID: 31390972
[TBL] [Abstract][Full Text] [Related]
12. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
[TBL] [Abstract][Full Text] [Related]
13. Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis).
Korjian S; Daaboul Y; Laliberté F; Zhao Q; Mehran R; Bode C; Halperin J; Verheugt FWA; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM; Pinto DS;
Am J Cardiol; 2019 Feb; 123(3):355-360. PubMed ID: 30502047
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
15. Comparative Safety and Efficacy of Eight Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Liang B; Zhu YC; Gu N
Front Cardiovasc Med; 2022; 9():832164. PubMed ID: 35387437
[TBL] [Abstract][Full Text] [Related]
16. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
De Vriese AS; Caluwé R; Pyfferoen L; De Bacquer D; De Boeck K; Delanote J; De Surgeloose D; Van Hoenacker P; Van Vlem B; Verbeke F
J Am Soc Nephrol; 2020 Jan; 31(1):186-196. PubMed ID: 31704740
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
Chi G; Kerneis M; Kalayci A; Liu Y; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
Am Heart J; 2018 Sep; 203():17-24. PubMed ID: 30015064
[TBL] [Abstract][Full Text] [Related]
19. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
[TBL] [Abstract][Full Text] [Related]
20. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
Engelberger RP; Noll G; Schmidt D; Alatri A; Frei B; Kaiser WE; Kucher N
Eur J Intern Med; 2015 Sep; 26(7):508-14. PubMed ID: 25935131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
